PTC Inc. logo

PTC Inc. (PTC)

Market Closed
5 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
173. 52
-4.98
-2.79%
After Hours
$
173. 99
+0.47 +0.27%
20.78B Market Cap
83.45 P/E Ratio
0% Div Yield
1,338,935 Volume
4.29 Eps
$ 178.5
Previous Close
Day Range
171.31 176.55
Year Range
133.38 219.69
Want to track PTC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 60 days
PTC Inc. (PTC) Q4 Earnings and Revenues Beat Estimates

PTC Inc. (PTC) Q4 Earnings and Revenues Beat Estimates

PTC Inc. (PTC) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.20 per share a year ago.

Zacks | 1 year ago
PTC forecasts quarterly revenue below estimates on tight tech spending

PTC forecasts quarterly revenue below estimates on tight tech spending

Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in demand for its industrial design and testing software as companies keep a tight leash on budgets.

Reuters | 1 year ago
PTC to Report Q4 Earnings: Here's What Investors Should Know

PTC to Report Q4 Earnings: Here's What Investors Should Know

PTC's fiscal fourth-quarter performance is likely to have been driven by strong business momentum across PLM and CAD segments amid forex fluctuations.

Zacks | 1 year ago
PTC Inc. (PTC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

PTC Inc. (PTC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Evaluate the expected performance of PTC Inc. (PTC) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks | 1 year ago
PTC Inc. (PTC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

PTC Inc. (PTC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

PTC Inc. (PTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Will PTC's AWS Partnership to Enhance Onshape Drive Stock Upward?

Will PTC's AWS Partnership to Enhance Onshape Drive Stock Upward?

PTC Inc. PTC has inked a Strategic Collaboration Agreement with Amazon Web Services (“AWS”) to boost the growth of its Onshape solution. This collaboration aims to enhance Onshape's capabilities, promote customer adoption and advance AI initiatives, all intended to help designers and engineers create high-quality products more swiftly and efficiently.

Zacks | 1 year ago
2 Stocks Down 66% and 8% to Buy Right Now

2 Stocks Down 66% and 8% to Buy Right Now

Roblox is posting very strong growth, but its stock still trades far below its previous high. Despite challenging end-market trends, software company PTC keeps generating double-digit growth in its key metric.

Fool | 1 year ago
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

PTC Therapeutics, Inc. achieved dose-dependent lowering of mutant Huntingtin protein in both the blood and CSF of HD patients, using 5 mg and 10 mg of PTC518. The global Huntington's Disease treatment market is expected to reach $3.06 billion by 2033. NDA of sepiapterin for the treatment of patients with phenylketonuria submitted July 2024.

Seekingalpha | 1 year ago
PTC Inc. (PTC) Up 0.7% Since Last Earnings Report: Can It Continue?

PTC Inc. (PTC) Up 0.7% Since Last Earnings Report: Can It Continue?

PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
1 Magnificent Software Stock Down 10% to Buy and Hold Forever

1 Magnificent Software Stock Down 10% to Buy and Hold Forever

The annual run rate of recurring revenue continues to grow at a double-digit rate. Free cash flow is growing more than recurring revenue growth.

Fool | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
Loading...
Load More